Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor
description
Transcript of Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor
![Page 1: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/1.jpg)
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw,
unedited content. Select slides from the original presentation are omitted where Research To
Practice was unable to obtain permission from the publication source and/or author. Links to view the actual reference materials have been provided for
your use in place of any omitted slides.
![Page 2: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/2.jpg)
![Page 3: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/3.jpg)
Targeting MET in NSCLC
John Heymach, MD, PhDAssociate Professor
Thoracic/Head and Neck Medical Oncology and Cancer Biology
9th Annual Winter Lung Cancer Conference
Hollywood, FLFeb. 11, 2012
![Page 4: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/4.jpg)
The hepatocyte growth factor/c-Met signaling pathway in cancer
Adapted from Liu, Trends Mol Med, 2010; Mayor, Lancet Oncology, 2011
• Met Small Molecule Inhibitors
– XL184
– ARQ197
– PF-02341066/Crizotinib
– BMS-777607
• Met/HGF Antibodies
– MetMAb
– AMG102
Therapeutic antibodies(e.g., AMG102, MetMAb, TAK-701 and SCH900105)
C-MET kinase inhibitors(e.g., ARQ197, PF2341066. PF4217903, JNJ38877606, INCB028060, XL880, XL184, MP470, MK2461, MGCD265, BMS777607, and AMG208)
Interacting proteins(e.g., RON, EGFRs, 6ß4 integrin, plexin B1, CD44, and FAS)
TRENDS in Molecular Medicine
![Page 5: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/5.jpg)
c-MET as a Therapeutic Target in NSCLC
• HGF/MET axis is associated with invasiveness and is regulated in part by the HIF and EGFR pathways
• MET amplifications are associated with EGFR inhibitor resistance
• HGF/MET may promote resistance to VEGF inhibitors
Xu L, et al. Oncogene. 2010;29:2616-2627. Engelman JA, et al. Science. 2007;316:1039-1043. Cascone, et al. ASCO 2010.
![Page 6: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/6.jpg)
c-Met receptor tyrosine kinase inhibitors – promising therapeutic target in NSCLC
Schiller JH, et al. J Clin Oncol 2010;28:18s (abstr LBA7502 and oral presentation)
• ARQ-197, a novel and selective non-ATP competitive inhibitor of c-MET
• ARQ 209 enrolled 167 advanced NSCLC patients
Endpoints
•Primary: PFS
•Secondary: ORR, OS
•Subset analyses
•Crossover: ORR
RANDOMIZE
Erlotinib 150 mg PO QD + ARQ 197 360 mg PO BID
28-day cycle
Erlotinib 150 mg PO QD + Placebo
28-day cycle
PD
• 33 sites in 6 countries
• Study accrual over 11 months (10/08–9/09)
• Randomization stratified by prognostic factors including sex, age, smoking, histology, performance status, prior therapy, best response, and geography (US vs ex-US)
Randomized, placebo-controlled, double-blind clinical trial
NSCLC
•Inoperable locally adv/metastatic dz.1 prior chemo (no prior EGFR TKI)
![Page 7: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/7.jpg)
ARQ-197 plus erlotinib was associated with improvements in PFS and OS
compared with erlotinib alone
*Cox regression model. Schiller JH, et al. J Clin Oncol 2010;28:18s (abstr LBA7502 and oral presentation)
E + A (n = 84)
E + placebo (n = 83)
Hazard ratio p-value
PFS 16.1 weeks 9.7 weeks 0.68 <0.05
OS 36.6 weeks 29.4 weeks 0.68 0.52*
![Page 8: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/8.jpg)
PFS and OS benefits most pronounced in patients with non-squamous cell carcinoma
*Cox regression model. Schiller JH, et al. J Clin Oncol 2010;28:18s (abstr LBA7502 and oral presentation)
E + A (n = 84)
E + placebo (n = 59)
Hazard ratio p-value
PFS 18.9 weeks 9.7 weeks 0.61 <0.05*
OS 43.1 weeks 29.4 weeks 0.58 <0.05*
![Page 9: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/9.jpg)
PFS in histologic and molecular subgroups
Schiller JH, et al. J Clin Oncol 2010;28:18s (abstr LBA7502 and oral presentation)
c-MET FISH >5, HR = 0.45
KRAS mutant, HR = 0.18
![Page 10: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/10.jpg)
Arm A (n = 64)Erlotinib (150 qd-oral) + MetMAb (15 mg/kg IV q3w)
Addition of MetMAb*
Stratification factors:
Tobacco history
Performance status
Histology
PD
* If eligible
Co-primary objectives: PFS in “Met High” patients PFS in overall ITT population Other key objectives: OS in “Met High” patients OS in overall ITT patients Overall response rate Safety/tolerability
OAM4558g study design: randomized Phase II study of erlotinib +/- MetMAb
Arm B (n = 64)
Erlotinib (150 qd-oral) +placebo (IV q3w)
Key eligibility:
• Stage IIIB/IV NSCLC
• 2nd/3rd-line NSCLC
• Tissue required
• PS 0–2
RANDOMIZATION
1:1n = 128
n = 23-Enrollment from 3/2009 to 3/2010-Data cut-off: 8 June 2010
Spigel et al, J Clin Oncol 29: 2011 (suppl; abstr 7505)
![Page 11: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/11.jpg)
PFS and OS: ITT population
– Objective response rates: Erlotinib + Placebo n = 3 (4.7%), Erlotinib + MetMAb n = 4 (6.3%)
– 23 patients from the Erlotinib + Placebo arm crossed over to MetMAb
mPFS and mOS are consistent with previously reported findings in a similar disease setting
Spigel et al, J Clin Oncol 29: 2011 (suppl; abstr 7505)
Erlotinib + placebo (n = 64)
Erlotinib + MetMAb(n = 64)
HR (95% CI)
Log-rank p-value
Median PFS (wk)
11.1 9.6 1.09 (0.71-1.67) 0.6988
Median OS (mo)
8.2 7.1 1.09 (0.62-1.91) 0.7642
![Page 12: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/12.jpg)
PFS and OS: Met high population
MetMAb + Erlotinib improves both PFS and OS in Met high NSCLC patients
Spigel et al, J Clin Oncol 29: 2011 (suppl; abstr 7505)
Erlotinib + placebo (n = 30)
Erlotinib + MetMAb(n = 35)
HR (95% CI)
Log-rank p-value
Median PFS (wk)
6.4 12.4 0.56 (0.31-1.02) 0.0547
Median OS (mo)
7.4 7.7 0.55 (0.26-1.16) 0.1113
![Page 13: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/13.jpg)
PFS and OS: Met low population
Met low NSCLC patients do worse with MetMAb + Erlotinib
Spigel et al, J Clin Oncol 29: 2011 (suppl; abstr 7505)
Erlotinib + placebo (n = 29)
Erlotinib + MetMAb(n = 27)
HR (95% CI)
Log-rank p-value
Median PFS (wk)
11.4 6.0 2.01 (1.04-3.91) 0.0354
Median OS (mo)
9.2 5.5 3.02 (1.13-8.11) 0.0212
![Page 14: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/14.jpg)
HGF/MET axis and resistance to VEGF inhibitors
![Page 15: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/15.jpg)
Cascone, Proc AACR 2011
Stromal and tumor MET expression is increased in VEGFR TKI resistant
H1975 xenografts
![Page 16: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/16.jpg)
Ectopic HGF overexpression induces relative resistance to VEGF/R inhibition
in NSCLC xenografts
![Page 17: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/17.jpg)
Dual MET/VEGFR targeting is more effective than VEGFR
or MET targeting alone
![Page 18: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/18.jpg)
Patterns of tumor revascularization associated with VEGF inhibitor resistance: Normalized vs sprouting revascularization
Adapted from Cascone T et al. 2010
Acquired Resistance: Normalized Revascularization
Long-termAnti-VEGF
Short-term Anti-VEGF
Sensitive phaseReduced MVD
Primary Resistance:Sprouting Vascularization
Baseline
Tumor endothelium Tumor cells
Pericytes
HGF
![Page 19: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/19.jpg)
Elevations in bFGF and HGF Develop Prior to Progression on Bevacizumab and Chemotherapy
Kopetz et al, JCO 2010
"Several proangiogenic cytokines were elevated before progression, notably basic fibroblast growth factor (bFGF),
PlGF, and HGF."
![Page 20: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/20.jpg)
Summary
• MET and its ligand HGF are overexpressed in cancers and are associated with metastatic spread
• MET may contribute to resistance to EGFR, VEGF inhibitors– Amplification of MET gene seen in some cases of acquired
resistance to EGFR TKIs in NSCLC
• MET inhibition shows promise in MET+ tumors in combination with erlotinib
• Phase III trials in progress in NSCLC– Erlotinib +/- MetMAb
– Erlotinib +/- ARQ197
![Page 21: Targeting MET in NSCLC John Heymach, MD, PhD Associate Professor](https://reader035.fdocuments.in/reader035/viewer/2022062305/56815a6a550346895dc7bf80/html5/thumbnails/21.jpg)
Saturday, February 11, 2012Hollywood, Florida
Faculty
Co-ChairsRogerio C Lilenbaum, MDMark A Socinski, MD
Co-Chair and ModeratorNeil Love, MD
Chandra P Belani, MDJohn Heymach, MD, PhDPasi A Jänne, MD, PhD
Thomas J Lynch Jr, MDHeather Wakelee, MD